Toxaphene
SmallMolecule
T3DB_ID
T3D0031
描述
Toxaphene is an insecticide mixture of compounds. It was once widenly used, but it is now banned in most areas due to its toxicity and tendency to bioaccumulate in the environment. (L107) The structure displayed is a generic structure of toxaphene components.
类别
"Pesticide", "Pollutant", "Airborne Pollutant", "Synthetic Toxin"
同义词
"Camphechlor", "Chlorcamphene", "Chlorinated camphene", "Polychlorochamphene"
CAS登记号
8001-35-2
化学式
C10H8Cl8
平均分子量
411.795
单同位素质量
407.813421912
IUPAC 名称
1,4,5,6,7,7-hexachloro-2,2-bis(chloromethyl)-3-methylidenebicyclo[2.2.1]heptane
传统名称
toxaphene
简化分子线性输入规范
ClCC1(CCl)C(=C)C2(Cl)C(Cl)C(Cl)C1(Cl)C2(Cl)Cl
InChI 标识符
InChI=1S/C10H8Cl8/c1-4-7(2-11,3-12)9(16)6(14)5(13)8(4,15)10(9,17)18/h5-6H,1-3H2
InChIKey=OEJNXTAZZBRGDN-UHFFFAOYSA-N
化合物类型
Organic compounds
大分类
Lipids and lipid-like molecules
类型
Prenol lipids
子类
Monoterpenoids
直接大类
Bicyclic monoterpenoids
另外分类
"Alkyl chlorides", "Hydrocarbon derivatives", "Organochlorides"
取代基
"Aliphatic homopolycyclic compound", "Alkyl chloride", "Alkyl halide", "Bicyclic monoterpenoid", "Hydrocarbon derivative", "Organochloride", "Organohalogen compound"
分子框架
Aliphatic homopolycyclic compounds
外部描述符
""
地位
Detected and Not Quantified
起源
Exogenous
蜂窝位置
"Membrane"
生物流体位置
组织位置
途径
状态
Solid
外貌
Yellow solid.
熔点/沸点/溶解度
77°C//0.00055 mg/mL at 20 °C [MURPHY,TJ et al. (1987)]
日志P
暴露途径
Oral (L107) ; inhalation (L107)
毒性机制
Toxaphene is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.
代谢
Toxaphene is absorbed through the intestines and lungs, then distributed mainly to fat tissues. Due to the complex composition of toxaphene, it requires various metabolic pathways to degrade, which involve dechlorination, dehydrodechlorination, and oxidation. Metabolism occurs primarily by hepatic mixed-function oxidases, and metabolites are excreted in the urine and faeces. (L107)
毒性值
LD50: 50 mg/kg (Oral, Rat) (L147) LD50: 600 mg/kg (Dermal, Rat) (L147)
致死剂量
2 to 7 grams for an adult human. (183)
致癌性
2B, possibly carcinogenic to humans. (L135)
用途/来源
Toxaphene was used as an insecticide. (L107)
最低风险等级
Acute Oral: 0.005 mg/kg/day (L134) Intermediate Oral: 0.001 mg/kg/day (L134)
健康影响
Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Certain reproductive effects in fertility, growth, and development for males and females have been linked specifically to organophosphate pesticide exposure. Most of the research on reproductive effects has been conducted on farmers working with pesticides and insecticdes in rural areas. In females menstrual cycle disturbances, longer pregnancies, spontaneous abortions, stillbirths, and some developmental effects in offspring have been linked to organophosphate pesticide exposure. Prenatal exposure has been linked to impaired fetal growth and development. Neurotoxic effects have also been linked to poisoning with OP pesticides causing four neurotoxic effects in humans: cholinergic syndrome, intermediate syndrome, organophosphate-induced delayed polyneuropathy (OPIDP), and chronic organophosphate-induced neuropsychiatric disorder (COPIND). These syndromes result after acute and chronic exposure to OP pesticides.
症状
Symptoms of low dose exposure include excessive salivation and eye-watering. Acute dose symptoms include severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Hypertension, hypoglycemia, anxiety, headache, tremor and ataxia may also result.
治疗
If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally.
药库 ID
HMDB_ID
PubChem 化合物 ID
5284469
维基百科链接
创建于
2009-03-06 18:57:57 UTC
更新于
2014-12-24 20:20:55 UTC
目标
毒素T3DB ID毒素名称目标名称
T3D0031 Toxaphene Progesterone receptor
T3D0031 Toxaphene Steroid hormone receptor ERR1
T3D0031 Toxaphene Androgen receptor
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit theta
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit rho-3
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit gamma-1
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit epsilon
T3D0031 Toxaphene Acetylcholinesterase
T3D0031 Toxaphene Adenylate cyclase type 9
T3D0031 Toxaphene Adenylate cyclase type 8
T3D0031 Toxaphene Adenylate cyclase type 7
T3D0031 Toxaphene Adenylate cyclase type 6
T3D0031 Toxaphene Adenylate cyclase type 5
T3D0031 Toxaphene Adenylate cyclase type 4
T3D0031 Toxaphene Adenylate cyclase type 3
T3D0031 Toxaphene Adenylate cyclase type 2
T3D0031 Toxaphene Adenylate cyclase type 10
T3D0031 Toxaphene Adenylate cyclase type 1
T3D0031 Toxaphene Sarcoplasmic/endoplasmic reticulum calcium ATPase 3
T3D0031 Toxaphene Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
T3D0031 Toxaphene Sarcoplasmic/endoplasmic reticulum calcium ATPase 1
T3D0031 Toxaphene Plasma membrane calcium-transporting ATPase 4
T3D0031 Toxaphene Plasma membrane calcium-transporting ATPase 3
T3D0031 Toxaphene Plasma membrane calcium-transporting ATPase 2
T3D0031 Toxaphene Plasma membrane calcium-transporting ATPase 1
T3D0031 Toxaphene Calcium-transporting ATPase type 2C member 2
T3D0031 Toxaphene Calcium-transporting ATPase type 2C member 1
T3D0031 Toxaphene Estrogen receptor beta
T3D0031 Toxaphene Estrogen receptor alpha
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit gamma
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit beta-3
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit beta-2
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit beta-1
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit alpha-4
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit alpha-3
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit alpha-2
T3D0031 Toxaphene Sodium/potassium-transporting ATPase subunit alpha-1
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit rho-2
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit rho-1
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit pi
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit gamma-3
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit gamma-2
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit delta
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit beta-3
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit beta-2
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit beta-1
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit alpha-6
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit alpha-5
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit alpha-4
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit alpha-3
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit alpha-2
T3D0031 Toxaphene Gamma-aminobutyric acid receptor subunit alpha-1

最新招商产品更多>>

免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:33068302000535
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3